{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"Phase II - To determine the time to AML transformation of participants on Ruxolitinib. Acute myeloid leukemia (AML) transformation according to World Health Organization (WHO) criteria. CMML-1: peripheral blood \\<5% blasts, bone marrow \\<10% myeloblast. CMML-2: peripheral blood \\<19 percent blasts persistent monocytosis \\>1000/ul +/- cytopenias Leukocytosis frequent, bone marrow \\<19 percent blasts \\>10% dysplasia in affected lineage, Auer Rods.","groups":[{"description":"All participants who received at least one dose of Ruxuxolitinib","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Percentage of Participants With Acute Myeloid Leukemia (AML) Transformation","type":"SECONDARY","unitOfMeasure":"percentage of patients"}